Tag: licensing
-
Drug Delivery Technology Licensed in $2B Deals
The biotechnology company Halozyme Therapeutics Inc. is licensing its technology for making infusion drugs deliverable with injections to two more drug makers.
-
Trial Shows Antibody Effective Against Asthma
Results from a large-scale clinical trial show a synthetic antibody, when added to standard treatments, reduces asthma attacks and improves lung functioning.
-
Trial Underway Testing Alzheimer’s-Schizophrenia Drug
A new clinical trial began in the U.K. in a test of an experimental drug to treat schizophrenia associated with Alzheimer’s disease.
-
Engineered T-Cell Company Acquired for $11.9 Billion
A company developing personal cancer therapies that genetically engineer a patient’s immune system cells is being acquired in a deal valued at $11.9 billion.
-
AstraZeneca, Biotech Partner on Messenger RNA Therapies
Global drug maker AstraZeneca is acquiring an option to license the rights to a technology based on genetic material transcribed from DNA, for new respiratory disease treatments.
-
Peptide Immunotherapy Shown Safe for Type 1 Diabetes
In an early clinical trial, researchers in the U.K. show treatments with peptides, fragments of proteins, are safe and can slow the progression of type 1 diabetes.
-
University Spins Off Educational Robot Start-Up
A start-up enterprise spun-off from Harvard University is developing a learning system with robotics to teach computer coding to students.
-
Trial to Test Inhaled Insulin, App for Diabetes Mgmt
A clinical trial is planned to test the benefits of managing type 2 diabetes with an inhaled formulation of insulin and a smartphone app.
-
Migraine Treatment Shown Effective in Late Trial
Results of a clinical trial show a single dose of new drug relieved migraine pain among more people with the condition, compared to a placebo.
-
Gene Editing, Therapy Company Gains $83.5M in Venture Funds
A biotechnology company designing treatments with gene edits and transfers using benign viruses is raising $83.5 million in its second venture funding round.